What is Baxalta Long-Term Capital Lease Obligation?
Baxalta's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2016 was $0 Mil.
Baxalta's quarterly Long-Term Capital Lease Obligation
declined
from Sep. 2015 ($5,277 Mil) to Dec. 2015 ($0 Mil) but then
stayed the same
from Dec. 2015 ($0 Mil) to Mar. 2016 ($0 Mil).
Baxalta's annual Long-Term Capital Lease Obligation
declined
from Dec. 2013 ($14 Mil) to Dec. 2014 ($0 Mil) but then
stayed the same
from Dec. 2014 ($0 Mil) to Dec. 2015 ($0 Mil).
Baxalta Long-Term Capital Lease Obligation Historical Data
The historical data trend for Baxalta's Long-Term Capital Lease Obligation can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Baxalta (NYSE:BXLT) Long-Term Capital Lease Obligation Explanation
Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.
Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:
1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.
Baxalta Long-Term Capital Lease Obligation Related Terms
Thank you for viewing the detailed overview of Baxalta's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.
Baxalta Inc was incorporated on September 8, 2016. It is a biopharmaceutical company engaged in the field of unmet medical needs covering various diseases which includes haemophilia, immunology and oncology. The Company develops, manufactures and markets a diverse portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions, as well as oncology treatments for acute lymphoblastic leukemia. It also invests in emerging technology platforms, including gene therapy and biosimilars. Its competitors include Advate, Feiba, Gammagard. The Company is subject to rules and regulations put forth by the jurisdiction it operates in.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BXLT has been successfully added to your 